Effects of stability on the biological function of p53.
The core domain of the tumor suppressor p53 has low thermodynamic stability, and many oncogenic mutations cause it to denature rapidly at body temperature. We made a series of core domain mutants that are significantly less or more stable than wild type to investigate effects of stability on the transcriptional activity and levels of native full-length p53 in H1299 mammalian cells. The levels of transcriptionally inactive native protein with inactivating mutations in the N-terminal transactivation domain correlated strongly with stability. The levels of transcriptionally active proteins, however, depended on both their stability and the transcriptional activity that leads to the feedback loop of proteolytic degradation via transcription of E3 ligases. A very highly stabilized quadruple mutant and an even more stable hexamutant were more active than wild-type p53 in terms of Bax transcription and apoptotic activity, and reached higher levels than wild type in cells. The increased activity did not result from increased overall stability but was due to a single known suppressor mutation, N239Y. It is possible that the low intrinsic stability of p53 is a means of keeping its level low in the cell by spontaneous denaturation, by a route additional to that of proteolytic degradation via E3 ligase pathways. Denatured p53 does accumulate in cells, and there are pathways for the proteolysis of denatured proteins.
Khoo
Kian Hoe
KH
Medical Research Council Centre for Protein Engineering, Cambridge CB2 0QH, United Kingdom.
Mayer
Sebastian
S
Fersht
Alan R
AR
D002460:Cell Line; D002470:Cell Survival; D006801:Humans; D009154:Mutation; D055550:Protein Stability; D017434:Protein Structure, Tertiary; D014158:Transcription, Genetic; D015533:Transcriptional Activation; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*
D016159:Tumor Suppressor Protein p53
Mol Cell. 2006 Jul 21;23(2):251-63
16857591
Biochemistry. 2008 Mar 11;47(10):3235-44
18260640
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5762-7
18391200
Protein Eng Des Sel. 2009 Jul;22(7):421-30
19515728
Oncogene. 2000 Mar 2;19(10):1245-56
10713666
J Biol Chem. 2004 Jan 9;279(2):1291-6
14534297
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2109-14
16461916
EMBO J. 2000 Feb 1;19(3):370-8
10654936
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7
14595027
Nature. 1997 May 15;387(6630):299-303
9153396
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14338-42
9405613
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14675-80
9843948
J Neurochem. 2002 Oct;83(1):176-85
12358741
J Biol Chem. 1998 May 22;273(21):13030-6
9582339
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15056-61
17015838
J Mol Biol. 2007 Sep 7;372(1):268-76
17631895
J Biol Chem. 2003 Jun 27;278(26):24108-12
12700230
Hum Mutat. 2002 Jun;19(6):607-14
12007217
EMBO J. 1998 Apr 1;17(7):1847-59
9524109
Science. 2003 Jan 17;299(5605):408-11
12481023
Oncogene. 1997 Aug 14;15(7):807-16
9266967
Cell Cycle. 2005 Aug;4(8):1015-8
16082197
J Biol Chem. 2006 Aug 4;281(31):21934-21941
16754663
Physiol Rev. 2002 Apr;82(2):373-428
11917093
J Cell Sci. 2000 May;113 ( Pt 10):1661-70
10769197
Genes Dev. 1993 Jul;7(7A):1126-32
8319905
Cell. 2003 Mar 21;112(6):779-91
12654245
Cell Death Differ. 2010 Jan;17(1):93-102
19498444
Mol Cell Biol. 2006 Mar;26(6):2297-308
16508005
Oncogene. 1999 Apr 8;18(14):2405-10
10327062
Curr Opin Cell Biol. 2003 Apr;15(2):164-71
12648672
EMBO J. 1993 Feb;12(2):461-8
8440237
J Mol Biol. 1999 Jan 29;285(4):1869-86
9917418
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12324-9
17620598
J Biol Chem. 2001 Oct 5;276(40):37390-401
11477076
Nat Biotechnol. 1999 Jul;17(7):691-5
10404163
EMBO J. 1994 Jun 1;13(11):2535-44
8013454
Nature. 2004 May 6;429(6987):86-92
15103385
Nature. 2000 Nov 16;408(6810):307-10
11099028
Nat Rev Cancer. 2001 Oct;1(1):68-76
11900253
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1227-32
16432196
Annu Rev Biochem. 2008;77:557-82
18410249
Nat Rev Cancer. 2006 Dec;6(12):909-23
17128209